https://m2.mtmt.hu/ eng 2026-05-31 14:14 JournalArticle 34545400 VALIDATED true Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, Budapest, H-1085, Hungary Department of Laboratory Medicine and Pathology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, United States Cited By :1 Export Date: 17 June 2024 Correspondence Address: Khoor, A.; Department of Laboratory Medicine and Pathology, 4500 San Pablo Road, United States; email: khoor.andras@mayo.edu 0 false 2026-05-23T13:05:05.215+0000 2024-02-20T07:24:18.080+0000 2024-01-30T14:24:42.799+0000 true 10022176 Laczik Cecilia /api/admin/10022176 Admin Cecilia Laczik (SE_AOK_1Patológia_Admin5_LC, admin) true 10022176 2026-02-12T09:15:24.814+0000 2024-02-09T11:14:54.979+0000 true 10069305 Kondor Zóra /api/admin/10069305 Admin Zóra Kondor (SE_KK_Admin5_KZ, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Survey paper (Journal Article) 102 true 1134514 true 1 /api/category/1 Category Scientific true 1 Szalai, Fatime true true /api/journal/10032813 REVIEWED CANCERS 2072-6694 true false 10032813 false 10032813 true 2072-6694 Journal FOREIGN 16 3 543 543 16 2024 Lung carcinoma is one of the most common cancer types for both men and women. Despite recent breakthroughs in targeted therapy and immunotherapy, it is characterized by a high metastatic rate, which can significantly affect quality of life and prognosis. Rictor (encoded by the RICTOR gene) is known as a scaffold protein for the multiprotein complex mTORC2. Among its diverse roles in regulating essential cellular functions, mTORC2 also facilitates epithelial–mesenchymal transition and metastasis formation. Amplification of the RICTOR gene and subsequent overexpression of the Rictor protein can result in the activation of mTORC2, which promotes cell survival and migration. Based on recent studies, RICTOR amplification or Rictor overexpression can serve as a marker for mTORC2 activation, which in turn provides a promising druggable target. Although selective inhibitors of Rictor and the Rictor-mTOR association are only in a preclinical phase, they seem to be potent novel approaches to reduce tumor cell migration and metastasis formation. Here, we summarize recent advances that support an important role for Rictor and mTORC2 as potential therapeutic targets in the treatment of lung cancer. This is a traditional (narrative) review based on Pubmed and Google Scholar searches for the following keywords: Rictor, RICTOR amplification, mTORC2, Rictor complexes, lung cancer, metastasis, progression, mTOR inhibitors. Funding 2037010 /api/funding/2037010 (FK-128404) Funder: NRDIO false true Funding 2037011 /api/funding/2037011 (ÚNKP-23-4-II) Funder: Ministry for Innovation and Technology false true Funding 2037012 /api/funding/2037012 (ÚNKP-23-4-II-SE-9) false true true 2024 true true true false false GOLD 2026-05-23 false http://www.mdpi.com/journal/cancers/ 7 0 7 5 2 7 7 6 6 7 7 5 5 5 2 0 7 5 7 5 0 6 6 Folyóiratcikk Journal Article 24 7 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 3 1 3 1 2025 0 3 3 3 3 2026 0 1 1 1 1 Q1 false false false false 2024-01-29T14:26:17.974+0000 Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 6 12 1 7 0 true Language 10002 /api/language/10002 English Angol English true 2 true PersonAuthorship 114154958 /api/authorship/114154958 Szalai, Fatime [Szalai, Fatime (Tumorbiológia), author] Patológiai és Kísérleti Rákkutató Intézet (SU / FM / I) 1 0.143 true false false Author 10093618 /api/author/10093618 Fatime Szalai (Tumorbiológia) Szalai Fatime true true Szalai Fatime true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 114154959 /api/authorship/114154959 Sztankovics, Dániel* [Sztankovics, Dániel (Onkológia), author] Patológiai és Kísérleti Rákkutató Intézet (SU / FM / I) 2 0.143 true false false Author 10074525 /api/author/10074525 Dániel Sztankovics (Onkológia) Sztankovics Dániel true true Sztankovics Dániel true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 114154960 /api/authorship/114154960 Krencz, Ildikó [Krencz, Ildikó (Tüdődaganatok), author] Patológiai és Kísérleti Rákkutató Intézet (SU / FM / I) 3 0.143 false false false Author 10051986 /api/author/10051986 Ildikó Krencz (Tüdődaganatok) Krencz Ildikó true 10051986 true Krencz Ildikó true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 114154961 /api/authorship/114154961 Moldvai, Dorottya [Moldvai, Dorottya (Tumorbiológia), author] Patológiai és Kísérleti Rákkutató Intézet (SU / FM / I) 4 0.143 false false false Author 10078438 /api/author/10078438 Dorottya Moldvai (Tumorbiológia) Moldvai Dorottya true true Moldvai Dorottya true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 114154962 /api/authorship/114154962 Pápay, Judit [Pápay, Judit (Patológia), author] Patológiai és Kísérleti Rákkutató Intézet (SU / FM / I) 5 0.143 false false false Author 10023572 /api/author/10023572 Judit Pápay (Patológia) Pápay Judit true 10023572 true Pápay Judit true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 114154963 /api/authorship/114154963 Sebestyén, Anna [Sebestyén, Anna (Tumorbiológia), author] Patológiai és Kísérleti Rákkutató Intézet (SU / FM / I) 6 0.143 false false false Author 10000745 /api/author/10000745 Anna Sebestyén (Tumorbiológia) Sebestyén Anna true 10000745 true Sebestyén Anna true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 114154964 /api/authorship/114154964 Khoor, Andras ✉ 7 0.143 false true true Khoor Andras true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PublicationIdentifier 25391887 /api/publicationidentifier/25391887 DOI: 10.3390/cancers16030543 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.3390/cancers16030543 https://doi.org/10.3390/cancers16030543 false true PublicationIdentifier 25682895 /api/publicationidentifier/25682895 WoS: 001160499900001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001160499900001 https://www.webofscience.com/wos/woscc/full-record/001160499900001 false true PublicationIdentifier 25626862 /api/publicationidentifier/25626862 Scopus: 85184728307 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85184728307 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85184728307 true true PublicationIdentifier 25626881 /api/publicationidentifier/25626881 PubMed: 38339294 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 38339294 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38339294&dopt=Abstract true true SjrRating 11488787 /api/sjrrating/11488787 sjr:Q1 (2024) Scopus - Oncology CANCERS 2072-6694 86 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2730 /api/classificationexternal/2730 Scopus - Oncology true 2730 true Q1 DIRECT true true Reference 49575621 /api/reference/49575621 1. Sung 2021: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries., CA Cancer J. Clin., 71, p. 209, DOI: 10.3322/caac.21660 1 10.3322/caac.21660 false true Reference 49575622 /api/reference/49575622 2. Alexander 2020: Update 2020: Management of Non-Small Cell Lung Cancer., Lung, 198, p. 897, DOI: 10.1007/s00408-020-00407-5 2 10.1007/s00408-020-00407-5 false true Reference 49575623 /api/reference/49575623 3. Gazdar 2017: Small-cell lung cancer: What we know, what we need to know and the path forward., Nat. Rev. Cancer, 17, p. 765, DOI: 10.1038/nrc.2017.106 3 10.1038/nrc.2017.106 false true Reference 49575624 /api/reference/49575624 4. Cheng 2016: The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics., J. Thorac. Oncol., 11, p. 1653, DOI: 10.1016/j.jtho.2016.05.021 4 10.1016/j.jtho.2016.05.021 false true Reference 49575625 /api/reference/49575625 5. Bade 2020: Lung Cancer 2020: Epidemiology, Etiology, and Prevention., Clin. Chest Med., 41, p. 1, DOI: 10.1016/j.ccm.2019.10.001 5 10.1016/j.ccm.2019.10.001 false true Reference 49575626 /api/reference/49575626 6. Nicholson 2022: The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015., J. Thorac. Oncol., 17, p. 362, DOI: 10.1016/j.jtho.2021.11.003 6 10.1016/j.jtho.2021.11.003 false true Reference 49575627 /api/reference/49575627 7. Travis 2013: New pathologic classification of lung cancer: Relevance for clinical practice and clinical trials., J. Clin. Oncol., 31, p. 992, DOI: 10.1200/JCO.2012.46.9270 7 10.1200/JCO.2012.46.9270 false true Reference 49575628 /api/reference/49575628 8. Caliman 2023: Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification., Lung Cancer, 175, p. 88, DOI: 10.1016/j.lungcan.2022.11.014 8 10.1016/j.lungcan.2022.11.014 false true Reference 49575629 /api/reference/49575629 9. Krencz 2020: mTOR in Lung Neoplasms., Pathol. Oncol. Res., 26, p. 35, DOI: 10.1007/s12253-020-00796-1 9 10.1007/s12253-020-00796-1 false true Reference 49575630 /api/reference/49575630 10. Sanaei 2022: The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles., Transl. Oncol., 18, p. 101364, DOI: 10.1016/j.tranon.2022.101364 10 10.1016/j.tranon.2022.101364 false true Reference 49575631 /api/reference/49575631 11. Peifer 2012: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer., Nat. Genet., 44, p. 1104, DOI: 10.1038/ng.2396 11 10.1038/ng.2396 false true Reference 49575632 /api/reference/49575632 12. Rudin 2012: Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer., Nat. Genet., 44, p. 1111, DOI: 10.1038/ng.2405 12 10.1038/ng.2405 false true Reference 49575633 /api/reference/49575633 13. George 2015: Comprehensive genomic profiles of small cell lung cancer., Nature, 524, p. 47, DOI: 10.1038/nature14664 13 10.1038/nature14664 false true Reference 49575634 /api/reference/49575634 14. Gardner 2017: Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis., Cancer Cell, 31, p. 286, DOI: 10.1016/j.ccell.2017.01.006 14 10.1016/j.ccell.2017.01.006 false true Reference 49575635 /api/reference/49575635 15. Umemura 2014: Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis., J. Thorac. Oncol., 9, p. 1324, DOI: 10.1097/JTO.0000000000000250 15 10.1097/JTO.0000000000000250 false true Reference 49575636 /api/reference/49575636 16. Wullschleger 2006: TOR signaling in growth and metabolism., Cell, 124, p. 471, DOI: 10.1016/j.cell.2006.01.016 16 10.1016/j.cell.2006.01.016 false true Reference 49575637 /api/reference/49575637 17. Gkountakos 2018: Unmasking the impact of Rictor in cancer: Novel insights of mTORC2 complex., Carcinogenesis, 39, p. 971, DOI: 10.1093/carcin/bgy086 17 10.1093/carcin/bgy086 false true Reference 49575638 /api/reference/49575638 18. Skoulidis 2019: Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy., Nat. Rev. Cancer, 19, p. 495, DOI: 10.1038/s41568-019-0179-8 18 10.1038/s41568-019-0179-8 false true Reference 49575639 /api/reference/49575639 19. Huang, S. (2020). mTOR Signaling in Metabolism and Cancer. Cells, 9., DOI: 10.3390/cells9102278 19 10.3390/cells9102278 false true Reference 49575640 /api/reference/49575640 20. Saxton 2017: mTOR Signaling in Growth, Metabolism, and Disease., Cell, 168, p. 960, DOI: 10.1016/j.cell.2017.02.004 20 10.1016/j.cell.2017.02.004 false true Reference 49575641 /api/reference/49575641 21. Liu 2020: mTOR at the nexus of nutrition, growth, ageing and disease., Nat. Rev. Mol. Cell Biol., 4, p. 183, DOI: 10.1038/s41580-019-0199-y 21 10.1038/s41580-019-0199-y false true Reference 49575642 /api/reference/49575642 22. Tian, T., Li, X., and Zhang, J. (2019). mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. Int. J. Mol. Sci., 20., DOI: 10.3390/ijms20030755 22 10.3390/ijms20030755 false true Reference 49575643 /api/reference/49575643 23. Fu, W., and Hall, M.N. (2020). Regulation of mTORC2 Signaling. Genes, 11., DOI: 10.3390/genes11091045 23 10.3390/genes11091045 false true Reference 49575644 /api/reference/49575644 24. Murugan 2019: mTOR: Role in cancer, metastasis and drug resistance., Semin. Cancer Biol., 59, p. 92, DOI: 10.1016/j.semcancer.2019.07.003 24 10.1016/j.semcancer.2019.07.003 false true Reference 49575645 /api/reference/49575645 25. Lamouille 2012: TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion., J. Cell Sci., 125, p. 1259, DOI: 10.1242/jcs.095299 25 10.1242/jcs.095299 false true Reference 49575646 /api/reference/49575646 26. Sun 2023: mTORC2: A multifaceted regulator of autophagy., Cell Commun. Signal., 21, p. 4, DOI: 10.1186/s12964-022-00859-7 26 10.1186/s12964-022-00859-7 false true Reference 49575647 /api/reference/49575647 27. Senoo 2019: Phosphorylated Rho-GDP directly activates mTORC2 kinase towards AKT through dimerization with Ras-GTP to regulate cell migration., Nat. Cell Biol., 21, p. 867, DOI: 10.1038/s41556-019-0348-8 27 10.1038/s41556-019-0348-8 false true Reference 49575648 /api/reference/49575648 28. Jebali 2018: The role of RICTOR downstream of receptor tyrosine kinase in cancers., Mol. Cancer, 17, p. 39, DOI: 10.1186/s12943-018-0794-0 28 10.1186/s12943-018-0794-0 false true Reference 49575649 /api/reference/49575649 29. Popova, N.V., and Jücker, M. (2021). The Role of mTOR Signaling as a Therapeutic Target in Cancer. Int. J. Mol. Sci., 22., DOI: 10.3390/ijms22041743 29 10.3390/ijms22041743 false true Reference 49575650 /api/reference/49575650 30. Sztankovics 2021: The role of metabolic ecosystem in cancer progression—Metabolic plasticity and mTOR hyperactivity in tumor tissues., Cancer Metastasis Rev., 40, p. 989, DOI: 10.1007/s10555-021-10006-2 30 10.1007/s10555-021-10006-2 false true Reference 49575651 /api/reference/49575651 31. Yamaguchi 2015: Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer., Cancer Sci., 106, p. 1687, DOI: 10.1111/cas.12828 31 10.1111/cas.12828 false true Reference 49575652 /api/reference/49575652 32. Grabiner 2014: A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity., Cancer Discov., 4, p. 554, DOI: 10.1158/2159-8290.CD-13-0929 32 10.1158/2159-8290.CD-13-0929 false true Reference 49575653 /api/reference/49575653 33. Wagle 2014: Response and acquired resistance to everolimus in anaplastic thyroid cancer., N. Engl. J. Med., 371, p. 1426, DOI: 10.1056/NEJMoa1403352 33 10.1056/NEJMoa1403352 false true Reference 49575654 /api/reference/49575654 34. Zhao 2020: The role of RICTOR amplification in targeted therapy and drug resistance., Mol. Med., 26, p. 20, DOI: 10.1186/s10020-020-0146-6 34 10.1186/s10020-020-0146-6 false true Reference 49575655 /api/reference/49575655 35. Pothongsrisit, S., and Pongrakhananon, V. (2021). Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products. Molecules, 26., DOI: 10.3390/molecules26134100 35 10.3390/molecules26134100 false true Reference 49575656 /api/reference/49575656 36. Ali 2022: Recent advances and limitations of mTOR inhibitors in the treatment of cancer., Cancer Cell Int., 22, p. 284, DOI: 10.1186/s12935-022-02706-8 36 10.1186/s12935-022-02706-8 false true Reference 49575657 /api/reference/49575657 37. Krencz 2017: Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma., Hum. Pathol., 62, p. 66, DOI: 10.1016/j.humpath.2016.12.012 37 10.1016/j.humpath.2016.12.012 false true Reference 49575658 /api/reference/49575658 38. Krencz 2019: Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma., Hum. Pathol., 93, p. 74, DOI: 10.1016/j.humpath.2019.08.018 38 10.1016/j.humpath.2019.08.018 false true Reference 49575659 /api/reference/49575659 39. Baker 2005: Stability of phosphoprotein as a biological marker of tumor signaling., Clin. Cancer Res., 11, p. 4338, DOI: 10.1158/1078-0432.CCR-05-0422 39 10.1158/1078-0432.CCR-05-0422 false true Reference 49575660 /api/reference/49575660 40. Sarbassov 2004: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton., Curr. Biol., 14, p. 1296, DOI: 10.1016/j.cub.2004.06.054 40 10.1016/j.cub.2004.06.054 false true Reference 49575661 /api/reference/49575661 41. Shaw 2006: Ras, PI(3)K and mTOR signalling controls tumour cell growth., Nature, 441, p. 424, DOI: 10.1038/nature04869 41 10.1038/nature04869 false true Reference 49575662 /api/reference/49575662 42. Jiang 2017: RICTOR expression in esophageal squamous cell carcinoma and its clinical significance., Med. Oncol., 34, p. 32, DOI: 10.1007/s12032-017-0894-5 42 10.1007/s12032-017-0894-5 false true Reference 49575663 /api/reference/49575663 43. Wazir 2013: Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer., Oncol. Rep., 29, p. 1969, DOI: 10.3892/or.2013.2346 43 10.3892/or.2013.2346 false true Reference 49575664 /api/reference/49575664 44. Joechle 2021: Role of mammalian target of rapamycin complex 2 in primary and secondary liver cancer., World J. Gastrointest. Oncol., 13, p. 1632, DOI: 10.4251/wjgo.v13.i11.1632 44 10.4251/wjgo.v13.i11.1632 false true Reference 49575665 /api/reference/49575665 45. Jebali, A., Battistella, M., Lebbé, C., and Dumaz, N. (2021). RICTOR Affects Melanoma Tumorigenesis and Its Re-sistance to Targeted Therapy. Biomedicines, 9., DOI: 10.3390/biomedicines9101498 45 10.3390/biomedicines9101498 false true Reference 49575666 /api/reference/49575666 46. Bang 2020: Correlation between RICTOR overexpression and amplification in advanced solid tumors., Pathol.-Res. Pract., 216, p. 152734, DOI: 10.1016/j.prp.2019.152734 46 10.1016/j.prp.2019.152734 false true Reference 49575667 /api/reference/49575667 47. Cheng 2015: RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors., Cancer Discov., 5, p. 1262, DOI: 10.1158/2159-8290.CD-14-0971 47 10.1158/2159-8290.CD-14-0971 false true Reference 49575668 /api/reference/49575668 48. Sun, Y., Li, R., Nong, B., Songyang, Z., Wang, X., Ma, W., and Zhou, Q. (2023). A Comprehensive Pan-Cancer Analysis of the Potential Biological Functions and Prognosis Values of RICTOR. Genes, 14., DOI: 10.3390/genes14061280 48 10.3390/genes14061280 false true Reference 49575669 /api/reference/49575669 49. Masui 2015: Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance., Proc. Natl. Acad. Sci. USA, 112, p. 9406, DOI: 10.1073/pnas.1511759112 49 10.1073/pnas.1511759112 false true Reference 49575670 /api/reference/49575670 50. Goul 2023: The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease., Nat. Rev. Mol. Cell Biol., 24, p. 857, DOI: 10.1038/s41580-023-00641-8 50 10.1038/s41580-023-00641-8 false true Reference 49575671 /api/reference/49575671 51. Simcox 2022: The central moTOR of metabolism., Dev. Cell, 57, p. 691, DOI: 10.1016/j.devcel.2022.02.024 51 10.1016/j.devcel.2022.02.024 false true Reference 49575672 /api/reference/49575672 52. Moloughney 2016: mTORC2 Responds to Glutamine Catabolite Levels to Modulate the Hexosamine Biosynthesis Enzyme GFAT1., Mol. Cell, 63, p. 811, DOI: 10.1016/j.molcel.2016.07.015 52 10.1016/j.molcel.2016.07.015 false true Reference 49575673 /api/reference/49575673 53. Szwed 2021: Regulation and metabolic functions of mTORC1 and mTORC2., Physiol. Rev., 101, p. 1371, DOI: 10.1152/physrev.00026.2020 53 10.1152/physrev.00026.2020 false true Reference 49575674 /api/reference/49575674 54. Luo 2018: Weighing In on mTOR Complex 2 Signaling: The Expanding Role in Cell Metabolism., Oxidative Med. Cell. Longev., 2018, p. 7838647, DOI: 10.1155/2018/7838647 54 10.1155/2018/7838647 false true Reference 49575675 /api/reference/49575675 55. Ebner 2017: Localization of mTORC2 activity inside cells., J. Cell Biol., 216, p. 343, DOI: 10.1083/jcb.201610060 55 10.1083/jcb.201610060 false true Reference 49575676 /api/reference/49575676 56. Knudsen 2020: Growth Factor-Dependent and -Independent Activation of mTORC2., Trends Endocrinol. Metab., 31, p. 13, DOI: 10.1016/j.tem.2019.09.005 56 10.1016/j.tem.2019.09.005 false true Reference 49575677 /api/reference/49575677 57. Chantaravisoot, N., Wongkongkathep, P., Kalpongnukul, N., Pacharakullanon, N., Kaewsapsak, P., Ariyachet, C., Loo, J.A., Tamanoi, F., and Pisitkun, T. (2023). mTORC2 interactome and localization determine aggressiveness of high-grade glioma cells through association with gelsolin. Sci. Rep., 13., DOI: 10.1038/s41598-023-33872-y 57 10.1038/s41598-023-33872-y false true Reference 49575678 /api/reference/49575678 58. Frias 2006: mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s., Curr. Biol., 16, p. 1865, DOI: 10.1016/j.cub.2006.08.001 58 10.1016/j.cub.2006.08.001 false true Reference 49575679 /api/reference/49575679 59. Serrano 2013: Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial-mesenchymal transition (EMT)., Oncogene, 32, p. 50, DOI: 10.1038/onc.2012.30 59 10.1038/onc.2012.30 false true Reference 49575680 /api/reference/49575680 60. Gao 2010: Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction., Mol. Cell, 39, p. 797, DOI: 10.1016/j.molcel.2010.08.016 60 10.1016/j.molcel.2010.08.016 false true Reference 49575681 /api/reference/49575681 61. Pan 2015: Tetraspanin 8-rictor-integrin α3 complex is required for glioma cell migration., Int. J. Mol. Sci., 16, p. 5363, DOI: 10.3390/ijms16035363 61 10.3390/ijms16035363 false true Reference 49575682 /api/reference/49575682 62. Hagan 2008: A Rictor-Myo1c complex participates in dynamic cortical actin events in 3T3-L1 adipocytes., Mol. Cell. Biol., 28, p. 4215, DOI: 10.1128/MCB.00867-07 62 10.1128/MCB.00867-07 false true Reference 49575683 /api/reference/49575683 63. Zhang 2010: mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis., Cancer Res., 70, p. 9360, DOI: 10.1158/0008-5472.CAN-10-0207 63 10.1158/0008-5472.CAN-10-0207 false true Reference 49575684 /api/reference/49575684 64. Guo 2012: Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells., Biochem. Biophys. Res. Commun., 418, p. 426, DOI: 10.1016/j.bbrc.2012.01.054 64 10.1016/j.bbrc.2012.01.054 false true Reference 49575685 /api/reference/49575685 65. Bera 2014: microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion., Exp. Cell Res., 328, p. 99, DOI: 10.1016/j.yexcr.2014.06.022 65 10.1016/j.yexcr.2014.06.022 false true Reference 49575686 /api/reference/49575686 66. Tsirtsaki 2020: The focal adhesion protein Integrin-Linked Kinase (ILK) as an important player in breast cancer pathogenesis., Cell Adhes. Migr., 14, p. 204, DOI: 10.1080/19336918.2020.1829263 66 10.1080/19336918.2020.1829263 false true Reference 49575687 /api/reference/49575687 67. Mazur 2022: Integrin-linked kinase (ILK): The known vs. the unknown and perspectives., Cell. Mol. Life Sci., 79, p. 100, DOI: 10.1007/s00018-021-04104-1 67 10.1007/s00018-021-04104-1 false true Reference 49575688 /api/reference/49575688 68. Almasabi, S., Ahmed, A.U., Boyd, R., and Williams, B.R.G. (2021). A Potential Role for Integrin-Linked Kinase in Colorectal Cancer Growth and Progression via Regulating Senescence and Immunity. Front. Genet., 12., DOI: 10.3389/fgene.2021.638558 68 10.3389/fgene.2021.638558 false true Reference 49575689 /api/reference/49575689 69. Zhou 2022: Epithelial-mesenchymal reprogramming by KLF4-regulated Rictor expression contributes to metastasis of non-small cell lung cancer cells., Int. J. Biol. Sci., 18, p. 4869, DOI: 10.7150/ijbs.73548 69 10.7150/ijbs.73548 false true Reference 49575690 /api/reference/49575690 70. Lamouille 2014: Molecular mechanisms of epithelial-mesenchymal transition., Nat. Rev. Mol. Cell Biol., 15, p. 178, DOI: 10.1038/nrm3758 70 10.1038/nrm3758 false true Reference 49575691 /api/reference/49575691 71. Tanaka 2013: Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer., Cancer Biol. Ther., 14, p. 13, DOI: 10.4161/cbt.22625 71 10.4161/cbt.22625 false true Reference 49575692 /api/reference/49575692 72. Ribatti 2020: Epithelial-Mesenchymal Transition in Cancer: A Historical Overview., Transl. Oncol., 13, p. 100773, DOI: 10.1016/j.tranon.2020.100773 72 10.1016/j.tranon.2020.100773 false true Reference 49575693 /api/reference/49575693 73. Saleh 2018: RICTOR gene amplification is correlated with metastasis and therapeutic resistance in triple-negative breast cancer., Pharmacogenomics, 19, p. 757, DOI: 10.2217/pgs-2018-0019 73 10.2217/pgs-2018-0019 false true Reference 49575694 /api/reference/49575694 74. Schmidt 2018: Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis., Neoplasia, 20, p. 1198, DOI: 10.1016/j.neo.2018.10.001 74 10.1016/j.neo.2018.10.001 false true Reference 49575695 /api/reference/49575695 75. Gulhati 2011: mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways., Cancer Res., 71, p. 3246, DOI: 10.1158/0008-5472.CAN-10-4058 75 10.1158/0008-5472.CAN-10-4058 false true Reference 49575696 /api/reference/49575696 76. Dai 2019: The “other” mTOR complex: New insights into mTORC2 immunobiology and their implications., Am. J. Transplant., 19, p. 1614, DOI: 10.1111/ajt.15320 76 10.1111/ajt.15320 false true Reference 49575697 /api/reference/49575697 77. Diz-Muñoz, A., Thurley, K., Chintamen, S., Altschuler, S.J., Wu, L.F., Fletcher, D.A., and Weiner, O.D. (2016). Membrane Tension Acts through PLD2 and mTORC2 to Limit Actin Network Assembly during Neutrophil Migration. PLoS Biol., 14., DOI: 10.1371/journal.pbio.1002474 77 10.1371/journal.pbio.1002474 false true Reference 49575698 /api/reference/49575698 78. Saha, S., Town, J.P., and Weiner, O.D. (2023). Mechanosensitive mTORC2 independently coordinates leading and trailing edge polarity programs during neutrophil migration. Mol. Biol. Cell, 34., DOI: 10.1091/mbc.E22-05-0191 78 10.1091/mbc.E22-05-0191 false true Reference 49575699 /api/reference/49575699 79. Prakash 2019: Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease., Nat. Commun., 10, p. 2110, DOI: 10.1038/s41467-019-10100-8 79 10.1038/s41467-019-10100-8 false true Reference 49575700 /api/reference/49575700 80. Sztankovics, D., Krencz, I., Moldvai, D., Dankó, T., Nagy, Á., Nagy, N., Bedics, G., Rókusz, A., Papp, G., and Tőkés, A.M. (2023). Novel RICTOR amplification harbouring entities: FISH validation of RICTOR amplification in tumour tissue after next-generation sequencing. Sci. Rep., 13., DOI: 10.1038/s41598-023-46927-x 80 10.1038/s41598-023-46927-x false true Reference 49575701 /api/reference/49575701 81. Sakre 2017: RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR., Oncotarget, 8, p. 5992, DOI: 10.18632/oncotarget.13362 81 10.18632/oncotarget.13362 false true Reference 49575702 /api/reference/49575702 82. Carracedo 2008: The PTEN-PI3K pathway: Of feedbacks and cross-talks., Oncogene, 27, p. 5527, DOI: 10.1038/onc.2008.247 82 10.1038/onc.2008.247 false true Reference 49575703 /api/reference/49575703 83. Uesugi 2011: The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer., Cancer Res., 71, p. 5765, DOI: 10.1158/0008-5472.CAN-11-0368 83 10.1158/0008-5472.CAN-11-0368 false true Reference 49575704 /api/reference/49575704 84. Janku 2018: Targeting the PI3K pathway in cancer: Are we making headway?., Nat. Rev. Clin. Oncol., 15, p. 273, DOI: 10.1038/nrclinonc.2018.28 84 10.1038/nrclinonc.2018.28 false true Reference 49575705 /api/reference/49575705 85. Eng 1984: Activity of rapamycin (AY-22,989) against transplanted tumors., J. Antibiot., 37, p. 1231, DOI: 10.7164/antibiotics.37.1231 85 10.7164/antibiotics.37.1231 false true Reference 49575706 /api/reference/49575706 86. Sehgal 1975: Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization., J. Antibiot., 28, p. 727, DOI: 10.7164/antibiotics.28.727 86 10.7164/antibiotics.28.727 false true Reference 49575707 /api/reference/49575707 87. Conciatori, F., Ciuffreda, L., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., and Milella, M. (2018). mTOR Cross-Talk in Cancer and Potential for Combination Therapy. Cancers, 10., DOI: 10.3390/cancers10010023 87 10.3390/cancers10010023 false true Reference 49575708 /api/reference/49575708 88. Alzahrani 2019: PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside., Semin. Cancer Biol., 59, p. 125, DOI: 10.1016/j.semcancer.2019.07.009 88 10.1016/j.semcancer.2019.07.009 false true Reference 49575709 /api/reference/49575709 89. Sarbassov 2005: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex., Science, 307, p. 1098, DOI: 10.1126/science.1106148 89 10.1126/science.1106148 false true Reference 49575710 /api/reference/49575710 90. Sabatini 2017: Twenty-five years of mTOR: Uncovering the link from nutrients to growth., Proc. Natl. Acad. Sci. USA, 114, p. 11818, DOI: 10.1073/pnas.1716173114 90 10.1073/pnas.1716173114 false true Reference 49575711 /api/reference/49575711 91. Basu 2018: Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer., Ann. Oncol., 29, p. 1918, DOI: 10.1093/annonc/mdy245 91 10.1093/annonc/mdy245 false true Reference 49575712 /api/reference/49575712 92. Werfel 2018: Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival., Cancer Res., 78, p. 1845, DOI: 10.1158/0008-5472.CAN-17-2388 92 10.1158/0008-5472.CAN-17-2388 false true Reference 49575713 /api/reference/49575713 93. Guenzle, J., Akasaka, H., Joechle, K., Reichardt, W., Venkatasamy, A., Hoeppner, J., Hellerbrand, C., Fichtner-Feigl, S., and Lang, S.A. (2020). Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma. Int. J. Mol. Sci., 22., DOI: 10.3390/ijms22010030 93 10.3390/ijms22010030 false true Reference 49575714 /api/reference/49575714 94. Bee 2018: Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: A prospective national cohort study., Thorax, 73, p. 369, DOI: 10.1136/thoraxjnl-2017-210872 94 10.1136/thoraxjnl-2017-210872 false true Reference 49575715 /api/reference/49575715 95. Revilla-López, E., Berastegui, C., Méndez, A., Sáez-Giménez, B., Ruiz de Miguel, V., López-Meseguer, M., Monforte, V., Bravo, C., Pujana, M.A., and Ramon, M.A. (2021). Long-term results of sirolimus treatment in lymphangioleiomyomatosis: A single referral centre experience. Sci. Rep., 11., DOI: 10.1038/s41598-021-89562-0 95 10.1038/s41598-021-89562-0 false true Reference 49575716 /api/reference/49575716 96. Takada 2016: Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis., Ann. Am. Thorac. Soc., 13, p. 1912, DOI: 10.1513/AnnalsATS.201605-335OC 96 10.1513/AnnalsATS.201605-335OC false true Reference 49575717 /api/reference/49575717 97. Krencz 2018: In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human Lymphangioleiomyomatosis., Hum. Pathol., 79, p. 199, DOI: 10.1016/j.humpath.2018.05.018 97 10.1016/j.humpath.2018.05.018 false true Reference 49575718 /api/reference/49575718 98. Jones 2019: Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2+/- Mice., Neoplasia, 21, p. 731, DOI: 10.1016/j.neo.2019.05.003 98 10.1016/j.neo.2019.05.003 false true Reference 49575719 /api/reference/49575719 99. Park 2020: Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy., Cancer, 126, p. 4002, DOI: 10.1002/cncr.33048 99 10.1002/cncr.33048 false true Reference 49575720 /api/reference/49575720 100. Zou, Y., Zheng, H., Ning, Y., Yang, Y., Wen, Q., and Fan, S. (2023). New insights into the important roles of phase seperation in the targeted therapy of lung cancer. Cell Biosci., 13., DOI: 10.1186/s13578-023-01101-8 100 10.1186/s13578-023-01101-8 false true /api/publication/34545400 Szalai Fatime et al. Rictor—A Mediator of Progression and Metastasis in Lung Cancer. (2024) CANCERS 2072-6694 16 3<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10093618"><a href="/gui2/?type=authors&mode=browse&sel=10093618" target="_blank">Szalai Fatime (<span class="authorship-author-name">Szalai Fatime</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10074525"><a href="/gui2/?type=authors&mode=browse&sel=10074525" target="_blank">Sztankovics Dániel^* (<span class="authorship-author-name">Sztankovics Dániel</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10051986"><a href="/gui2/?type=authors&mode=browse&sel=10051986" target="_blank">Krencz Ildikó (<span class="authorship-author-name">Krencz Ildikó</span> <span class="authorAux-mtmt"> Tüdődaganatok</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10078438"><a href="/gui2/?type=authors&mode=browse&sel=10078438" target="_blank">Moldvai Dorottya (<span class="authorship-author-name">Moldvai Dorottya</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10023572"><a href="/gui2/?type=authors&mode=browse&sel=10023572" target="_blank">Pápay Judit (<span class="authorship-author-name">Pápay Judit</span> <span class="authorAux-mtmt"> Patológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000745"><a href="/gui2/?type=authors&mode=browse&sel=10000745" target="_blank">Sebestyén Anna (<span class="authorship-author-name">Sebestyén Anna</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Khoor Andras ✉ </span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34545400" target="_blank">Rictor—A Mediator of Progression and Metastasis in Lung Cancer</a></div> <div> <span class="journal-title">CANCERS</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2072-6694">2072-6694</a>)</span>: <span class="journal-volume">16</span> <span class="journal-issue">3</span> <span class="page"> Paper 543. 16 p. </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Language: English | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.3390/cancers16030543" target="_blank" href="https://doi.org/10.3390/cancers16030543"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001160499900001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001160499900001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85184728307" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85184728307"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="38339294" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38339294&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Journal subject: Scopus - Oncology&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q1</div> <div class="journal-subject">Journal subject: Scopus - Cancer Research&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="" class="citingPub-count">Citing papers: 7</span> | Independent citation: 5 | Self citation: 2 | Unknown citation: 0 | Number of citations in WoS: 6 | Number of citations in Scopus:&nbsp;6 | WoS/Scopus assigned:&nbsp;7 | Number of citations with DOI:&nbsp;7 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34545400&sort=publishedYear,desc&sort=title"> Number of cited publications: 6 </a> </div> <div class="mtid"><span class="long-pub-mtid">Publication: 34545400</span> | <span class="status-data status-VALIDATED"> Validated </span> Core Citing | <span class="type-subtype">Journal Article ( Survey paper ) </span> | <span class="pub-category">Scientific</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (FK-128404) Funder: NRDIO, (ÚNKP-23-4-II) Funder: Ministry for Innovation and Technology, (ÚNKP-23-4-II-SE-9) </div> <div class="lastModified">Last Modified: 2024.02.20. 08:24 Ágnes Szalóky-Siki (SE_KK_Admin5_SZSA, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Comments</u>: Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, Budapest, H-1085, Hungary Department of Laboratory Medicine and Pathology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, United States Cited By :1 Export Date: 17 June 2024 Correspondence Address...</pre> </div></div>